Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

@article{Falini2005CytoplasmicNI,
  title={Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.},
  author={Brunangelo Falini and Cristina Mecucci and Enrico Tiacci and Myriam Alcalay and Roberto Rosati and Laura Pasqualucci and Roberta La Starza and Daniela Diverio and Emanuela Colombo and Antonella Santucci and Barbara Bigerna and Roberta Pacini and Alessandra Pucciarini and Arcangelo Liso and Marco Vignetti and Paola Fazi and Natalia Meani and Valentina Pettirossi and Giuseppe Saglio and Franco Mandelli and Francesco Lo‐Coco and Pier Giuseppe Pelicci and Massimo Fabrizio Martelli},
  journal={The New England journal of medicine},
  year={2005},
  volume={352 3},
  pages={
          254-66
        }
}
BACKGROUND Nucleophosmin (NPM), a nucleocytoplasmic shuttling protein with prominent nucleolar localization, regulates the ARF-p53 tumor-suppressor pathway. Translocations involving the NPM gene cause cytoplasmic dislocation of the NPM protein. METHODS We used immunohistochemical methods to study the subcellular localization of NPM in bone marrow-biopsy specimens from 591 patients with primary acute myelogenous leukemia (AML). We then correlated the presence of cytoplasmic NPM with clinical… Expand
Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype.
TLDR
The NPM1 mutation is a frequent abnormality in AML patients without known genetic marker; the mutation may represent a new target to monitor minimal residual disease inAML and a potential candidate for alternative and targeted treatments. Expand
Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm
TLDR
Evidence is provided that aberrant cytoplasmic dislocation of nucleophosmin – the immunohistochemical surrogate for NPM1 mutations – allows the two entities to be genetically separated and justify the inclusion of these pathological conditions as separate entities in the new WHO classification. Expand
Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.
TLDR
NPMc+ AML shows increased frequency in adults and females, wide morphologic spectrum, multilineage involvement, high frequency of FLT3-ITD, CD34 negativity, and a distinct gene-expression profile. Expand
Nucleophosmin: A versatile molecule associated with hematological malignancies
TLDR
This review focuses on the clinical significance of the NPM1 gene in hematological malignancies and newly discovered roles of NPM associated with oncogenesis. Expand
Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia.
TLDR
It is reported that for the first time, a patient with NPMc+ myeloid sarcoma of the skin presenting 20 years after diagnosis of AML remains in continuous complete haematological remission over a 20-year follow-up. Expand
Cytoplasmic Expression of Nucleophosmin 1 as a Marker for Diagnosing Residual Disease of Acute Myeloid Leukemia
  • Q. Dai, Yongsheng Ren
  • Medicine, Biology
  • Applied immunohistochemistry & molecular morphology : AIMM
  • 2013
TLDR
Subcellular localization of NPM1 as detected by IHC is stable during the course of the disease, and NPMc+ at follow-up supports residual disease in cases with NPMC+ at initial diagnosis. Expand
Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia
TLDR
This work describes for the first time a unique case of Philadelphia-positive chronic myeloid leukaemia (CML) presenting as myeloids blast crisis carrying cytoplasmic mutated NPM1, and shows distinctive molecular, immunophenotypic and clinical features. Expand
Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification.
TLDR
It is suggested that NPMc+ AML be provisionally regarded as a separate AML with prognostic significance and the value of FAB criteria in subdividing the WHO category of "AML not otherwise characterized" is questioned. Expand
Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia.
TLDR
Because alterations at C-terminus of leukemic NPM mutants are similar, immunohistochemistry detects all exon-12 NPM mutations and is a valuable, inexpensive tool in the diagnostic-prognostic work-up of patients with AML with normal karyotype. Expand
Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features.
  • B. Falini
  • Biology, Medicine
  • Cancer treatment and research
  • 2010
TLDR
Because of its distinctive molecular, pathological, immunophenotypic and prognostic features, AML with mutated NPM1 has been included, as a new provisional entity, in the 2008 World Health Organization (WHO) classification of myeloid neoplasms. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 41 REFERENCES
Detection of normal and chimeric nucleophosmin in human cells.
TLDR
Three new monoclonal antibodies are described, two of which recognize, by Western blotting, the N-terminal portion of NPM present in the N PM-ALK fusion protein and also in two other NPM fusion proteins (NPM-RARalpha and NPM-MLF1). Expand
Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis.
TLDR
The activation of the truncated ALK protein by a completely heterologous oligomerization domain suggests that the functionally important role of the NPM segment of NPM-ALK in transformation is restricted to the formation of kinase-active oligomers and does not involve the alteration of normal NPM functions. Expand
Nucleophosmin regulates the stability and transcriptional activity of p53
TLDR
It is shown that NPM interacts directly with the tumour suppressor p53, regulates the increase in stability and transcriptional activation of p53 after different types of stress, and induces p53-dependent premature senescence on overexpression in diploid fibroblasts. Expand
The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1.
TLDR
RNA-based polymerase chain reaction analysis revealed identical NPM-MLF1 mRNA fusions in each of the three t(3;5)-positive cases of AML examined, indicating that NPM trafficking signals direct MLF1 to an inappropriate cellular compartment in myeloid leukemia cells. Expand
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.
TLDR
Besides the importance of FLT3-LM for biologic and clinical characterization of AML, its value as a marker for disease monitoring based on 120 follow-up samples of 34 patients is shown. Expand
Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia
TLDR
Although there is an overlap in the mutational spectrum in AML with FLT3 ITD and MLL PTD mutations, the data do not support a common mechanistic basis and do not unequivocally support the notion that MLLPTD mutations represent an independent prognostic factor. Expand
Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol
TLDR
The results indicate that FLT3 alterations are associated in APL with more aggressive clinical features and suggest that these lesions may not play a major role in leukemia progression, while a trend towards inferior outcome was observed for ITD+ve cases when analyzing disease-free survival (DFS) and relapse risk (RR). Expand
Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry.
TLDR
Current immunocytochemical studies of the products of many rearranged genes in lymphoma and leukemia can be clinically informative and provide information on cellular and subcellular protein expression that cannot be inferred from studies based on messenger RNA. Expand
Lymphomas expressing ALK fusion protein(s) other than NPM-ALK.
TLDR
The results suggest that lymphomas carrying variants of the NPM-ALK fusion protein can be detected by immunostaining for ALK and NPM and also that they can be grouped with classical t(2;5)-positive tumors as a single entity that shows a better prognosis than ALK-negative anaplastic large-cell lymphomas. Expand
FLT3 mutations are associated with other molecular lesions in AML.
TLDR
The frequency of associated mutations in a consecutive series of adult de novo AML (353 patients) was determined to stress the validity of the cooperative model and the search for new tyrosine kinases which can be the target of molecular lesions in AML warrants further investigation. Expand
...
1
2
3
4
5
...